Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04334759 · FLOW

Participant flow

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma · Source last updated 2026-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab
    id
    FG000
    title
    Experimental Arm for Chemo Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance
  2. description
    Standard Chemotherapy for 4 to 6 cycles, followed by Observation
    id
    FG001
    title
    Control Arm for Chemo Cohort: Chemotherapy, Then Observation
  3. description
    Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab
    id
    FG002
    title
    Experimental Arm for IO Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance
  4. description
    Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.
    id
    FG003
    title
    Control Arm for IO Cohort: Ipilimumab and Nivolumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        6
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        6
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        5
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        2
      4. group Id
        FG003
        num Subjects
        1
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        1
      type
      Withdrawal by Subject
    5. reasons
      1. group Id
        FG000
        num Subjects
        87
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        11
      4. group Id
        FG003
        num Subjects
        13
      type
      Disease Progression
    6. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        5
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Not Treated
    7. reasons
      1. group Id
        FG000
        num Subjects
        5
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      Patient moved to off label supply of durvalumab following declaration of study closure by sponsor
    8. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Functional decline due to medical comorbidities
    9. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Required use of prohibited concomitant treatment
    10. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      The patient is not dead.
    11. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        2
      type
      Patient continuing with nivolumab treatment beyond declaration of study closure by sponsor
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        114
      2. group Id
        FG001
        num Subjects
        60
      3. group Id
        FG002
        num Subjects
        17
      4. group Id
        FG003
        num Subjects
        23
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        38
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        114
      2. group Id
        FG001
        num Subjects
        22
      3. group Id
        FG002
        num Subjects
        17
      4. group Id
        FG003
        num Subjects
        23
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab
    id
    FG000
    title
    Experimental Arm for Chemo Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance
  2. description
    Standard Chemotherapy for 4 to 6 cycles, followed by Observation
    id
    FG001
    title
    Control Arm for Chemo Cohort: Chemotherapy, Then Observation
  3. description
    Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab
    id
    FG002
    title
    Experimental Arm for IO Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance
  4. description
    Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.
    id
    FG003
    title
    Control Arm for IO Cohort: Ipilimumab and Nivolumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        6
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        6
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        5
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        2
      4. group Id
        FG003
        num Subjects
        1
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        1
      type
      Withdrawal by Subject
    5. reasons
      1. group Id
        FG000
        num Subjects
        87
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        11
      4. group Id
        FG003
        num Subjects
        13
      type
      Disease Progression
    6. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        5
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Not Treated
    7. reasons
      1. group Id
        FG000
        num Subjects
        5
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      Patient moved to off label supply of durvalumab following declaration of study closure by sponsor
    8. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Functional decline due to medical comorbidities
    9. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Required use of prohibited concomitant treatment
    10. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      The patient is not dead.
    11. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        2
      type
      Patient continuing with nivolumab treatment beyond declaration of study closure by sponsor
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        114
      2. group Id
        FG001
        num Subjects
        60
      3. group Id
        FG002
        num Subjects
        17
      4. group Id
        FG003
        num Subjects
        23
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        38
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        114
      2. group Id
        FG001
        num Subjects
        22
      3. group Id
        FG002
        num Subjects
        17
      4. group Id
        FG003
        num Subjects
        23
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice